RecruitingNCT07294170

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Sponsor

argenx

Enrollment

70 participants

Start Date

Dec 19, 2025

Study Type

OBSERVATIONAL

Conditions

Myasthenia Gravis Generalized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis gMG MG AChR-Ab Seropositive Generalized Myasthenia Gravis

Summary

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Efgartigimod IV and a biological treatment called Empasiprubart IV for people with achr-ab seropositive generalized myasthenia gravis, generalized myasthenia gravis, and other related conditions. The study is currently recruiting participants at 18 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALEfgartigimod IV

Intravenous infusion of efgartigimod

BIOLOGICALEmpasiprubart IV

Intravenous infusion of empasiprubart

Locations(18)

Profound Research LLC - Carlsbad

Carlsbad, California, United States

Visionary Investigators Network

Miami, Florida, United States

University of South Florida

Tampa, Florida, United States

Erlanger Health System

Columbia, Maryland, United States

Henry Ford Health System

Detroit, Michigan, United States

Dent Neurologic Institute - Amherst

Amherst, New York, United States

Duke Early Phase Clinical Research Unit - PPDS

Durham, North Carolina, United States

Ohio State Martha Morehouse Outpatient Care

Columbus, Ohio, United States

Erlanger Health System

Chattanooga, Tennessee, United States

National Neuromuscular Research Institute

Austin, Texas, United States

University of Texas- San Antonio - Health Science Center - PPDS

San Antonio, Texas, United States

UZ Leuven - PPDS

Leuven, Belgium

ASST Papa Giovanni XXIII - Ospedale Papa Giovanni XXIII

Bergamo, Lombardy, Italy

Fondazione IRCCS Istituto Neurologico Carlo Besta

Milan, Lombardy, Italy

MICS Centrum Medyczne Bydgoszcz

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Krakowska Akademia Neurologii Sp. z o.o.

Krakow, Lesser Poland Voivodeship, Poland

Centrum Medyczne Neurologia Slaska

Katowice, Silesian Voivodeship, Poland

Hospital Regional Universitario de Malaga - Hospital General

Málaga, Malaga, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07294170

Related Trials

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

NCT076736272 locations

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

NCT0622020135 locations

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

NCT06463587145 locations

A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)

NCT076737442 locations

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

NCT072472797 locations